We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Peripheral Metabolic Effects of Somatostatin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01062529
Recruitment Status : Completed
First Posted : February 4, 2010
Last Update Posted : January 21, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.

Condition or disease Intervention/treatment
Acromegaly Growth Hormone Deficiency Diabetes Drug: Somatostatin

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 8 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls
Study Start Date : October 2009
Primary Completion Date : February 2010
Study Completion Date : February 2010

Arms and Interventions

Arm Intervention/treatment
Experimental: somatostatin Drug: Somatostatin
4 h of 150 microgram infusion

Outcome Measures

Primary Outcome Measures :
  1. Plasma levels of glucose [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. GH signalling [ Time Frame: one year ]
  2. Serum levels of free fatty acids (FFA) [ Time Frame: one year ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI < 27 kg/m2
  • Written informed consent
  • Healthy

Exclusion Criteria:

  • Any disease
  • Any use of medications
  • Present or previous malignancy
  • Alcohol dependency
  • Allergy to trial medication
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01062529

Medical department M
Aarhus, Denmark, 8000
Sponsors and Collaborators
University of Aarhus
The Ministry of Science, Technology and Innovation, Denmark
Principal Investigator: Jens Otto L Jørgensen, Professor
More Information

Responsible Party: University of Aarhus
ClinicalTrials.gov Identifier: NCT01062529     History of Changes
Other Study ID Numbers: M-2008005
First Posted: February 4, 2010    Key Record Dates
Last Update Posted: January 21, 2013
Last Verified: January 2013

Keywords provided by University of Aarhus:
GH signalling
insulin resistance

Additional relevant MeSH terms:
Dwarfism, Pituitary
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs